Edition:
United Kingdom

PeptiDream Inc (4587.T)

4587.T on Tokyo Stock Exchange

4,220JPY
16 Jan 2018
Change (% chg)

¥-85 (-1.97%)
Prev Close
¥4,305
Open
¥4,290
Day's High
¥4,295
Day's Low
¥4,190
Volume
1,364,600
Avg. Vol
1,000,097
52-wk High
¥4,440
52-wk Low
¥2,550

Latest Key Developments (Source: Significant Developments)

Peptidream announces discovery collaboration agreement with Bayer
Monday, 20 Nov 2017 

Nov 19 (Reuters) - Peptidream Inc <4587.T>:Peptidream announces discovery collaboration agreement with bayer.‍Entered into a multi-target discovery collaboration with Germany-based Bayer AG​.Under terms , co would receive undisclosed upfront payment and research funding.Under terms, co is eligible to receive preclinical, clinical, commercialization milestone payments totaling up to $1.11 billion​.Also eligible to receive royalties on sales of any products that arise from collaboration​.  Full Article

PeptiDream announces discovery collaboration agreement with Bayer AG
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - PeptiDream Inc <4587.T>:Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG.Under the terms of the agreement, it would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.11 billion (124.5 billion yen) .In addition, it is eligible to receive royalties on sales of any products that arise from the collaboration .  Full Article

PeptiDream announces change of chairman and president
Tuesday, 22 Aug 2017 

Aug 22(Reuters) - PeptiDream Inc <4587.T>:Says it appoints current president Kiichi Kubota as chairman of the board of the company.Says it appoints Patrick Reid as new president of the company.Effective Sept. 27.  Full Article

Sosei Group subsidiary Heptares enters strategic collaboration with PeptiDream
Thursday, 29 Jun 2017 

June 29(Reuters) - Sosei Group Corp <4565.T>:Says its unit Heptares Therapeutics and PeptiDream Inc <<<4587.T>>>, a public Tokyo-based biopharmaceutical company, have entered into a strategic collaboration to discover, develop and commercialise novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) with an important role in inflammatory diseases.  Full Article

PeptiDream announces licensing of peptide discovery platform system (PDPS) technology to Shionogi
Monday, 12 Jun 2017 

June 12(Reuters) - PeptiDream Inc <4587.T>:Says it has entered into a technology license agreement with Osaka-based Shionogi & Co Ltd <<<4507.T>>>, to nonexclusively license PeptiDream’s proprietary Peptide discovery platform system (PDPS) technology.Under the terms of the agreement, PeptiDream is eligible to receive royalties on sales of certain products that arise from use of the PDPS technology.  Full Article

PeptiDream announces completion of technology transfer of Peptide Discovery Platform System to Lilly
Wednesday, 7 Jun 2017 

June 7(Reuters) - PeptiDream Inc <4587.T>:Says it completes the technology transfer of the Peptide Discovery Platform System (PDPS) to US-based Eli Lilly and Company.Under the terms of the technology license agreement entered into by the parties in March 2016, the co will receive a milestone payment, and is eligible to receive development milestones and royalties on future sales of products that arise from use of the PDPS technology.  Full Article

Peptidream announces license of PDPS technology to Genentech Inc
Wednesday, 20 Jul 2016 

PeptiDream Inc <4587.T>: Says it entered into a technology license agreement with U.S.-based company Genentech Inc to nonexclusively license PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology . Says PeptiDream will receive an undisclosed upfront payment, annual technology access payments, and is eligible to receive payments based on achievement of certain redetermined development milestones .Says PeptiDream is eligible to receive royalties on sales of certain products that arise from use of the PDPS technology.  Full Article

PeptiDream achieves milestone for initiation of clinical development for bristol-myers squibb’s first collaboration product candidate
Wednesday, 15 Jun 2016 

PeptiDream Inc <4587.T>: Says it has earned a milestone for the dosing of a first patient in a clinical trial by its alliance partner, Bristol-Myers Squibb Company (BMS) . Says this is the first program to enter clinical testing out of the discovery collaboration between the two companies .Says the molecule being advanced in clinical testing was discovered by Bristol-Myers Squibb starting from an active lead macrocyclic compound identified by Peptidream using its PDPS technology and provided to BMS for further optimization.  Full Article

PeptiDream signs joint research and development agreement with SAHI KASEI PHARMA
Monday, 28 Mar 2016 

PeptiDream Inc:Says signed joint research and development agreement with SAHI KASEI PHARMA CORPORATION on March 28 for creating of special cyclic peptide with respect to several drug target protein.  Full Article

PeptiDream announces non-exclusive distribution agreement with Eli Lilly and Company
Thursday, 3 Mar 2016 

PeptiDream Inc:Says reached an agreement with a U.S-based company Eli Lilly and Company, to grant Eli Lilly and Company the non-exclusive distribution rights on PDPS (Peptide Discovery Platform System).  Full Article